Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00746018
First received: September 2, 2008
Last updated: August 15, 2013
Last verified: August 2013

September 2, 2008
August 15, 2013
August 2008
August 2014   (final data collection date for primary outcome measure)
To determine if the LigaSure device, which we routinely used for removal of tubes and ovaries, is effective at destroying all tubal cells comprising the fallopian tube including those cells within the cornua of the uterus. [ Time Frame: conclusion of the study ] [ Designated as safety issue: No ]
To determine if the LigaSure device, which we routinely used for removal of tubes and ovaries, is effective at destroying all tubal cells comprosing the fallopian tube including those cells within the cornua of the uterus. [ Time Frame: conclusion of the study ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00746018 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy
Evaluation of Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy

Some patients, specifically those with a diagnosed genetic mutation, will have their ovaries and fallopian tubes removed without removal of the uterus in an attempt to prevent ovarian and fallopian tube cancer from developing.

Anatomically the fallopian tubes are attached to the uterus and extend towards the ovaries. The fallopian tube tissue arises within the corner area of the uterus and occupies about 1cm of the uterine muscle wall.

The purpose of this study is to determine if the technique used to remove fallopian tubes only (without removal of the uterus) adequately removes or destroys all the fallopian tube cells that remain in the uterine muscle wall.

Currently, during the operation an instrument is used that burns the fallopian tube and allows it to be cut away from the uterus. The investigators do not know if this procedure successfully destroys all the fallopian tube cells within the uterus. Therefore, we will compare this single step procedure to a two step procedure. The two step procedure is to burn and cut the fallopian tube followed by an additional burning step, called cauterization at the top of the uterus. The investigators will assess if either or both of these procedures destroy the fallopian tube cells that may remain inside the uterine wall. This is important to determine since the goal is to remove the ovaries and all of the fallopian tubes in order to prevent future development of ovarian or fallopian tube cancer.

Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Cervical Cancer
  • Ovarian Cancer
  • Uterine Cancer
Device: LigaSure vessel sealing system
The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
Experimental: 1
The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
Intervention: Device: LigaSure vessel sealing system
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
39
August 2014
August 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women undergoing a non-emergent total hysterectomy with removal of the tubes and ovaries by the gynecologic service for benign or malignant conditions uterine, cervical or early ovarian cancer.
  • Patients will undergo either a laparotomy, total laparoscopy or laparoscopically assisted vaginal hysterectomy
  • Patients will be 21 years and older.

Exclusion Criteria:

  • Patients with abnormal fallopian tubes seen preoperatively by radiologic exam or intraoperatively by visual inspection.
  • Patients who are suspected to have fallopian tube cancer prior to their surgery
  • Patients who have had prior pelvic radiation therapy
  • Patients who are undergoing a Robotically Assisted procedure
  • Patients who have had any type of prior tubal surgery
Female
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00746018
08-092
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Not Provided
Principal Investigator: Nadeem Abu-Rustum, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP